Albinterferon alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1

Gastroenterology

Volumn 139, Issue 4, 2010, Pages 1257-1266

  Zeuzem, Stefan ^a   Sulkowski, Mark S ^b   Lawitz, Eric J ^c   Rustgi, Vinod K ^d   Rodrigueztorres, Maribel ^e   Bacon, Bruce R ^f   Grigorescu, Mircea ^g   Tice, Alan D ^h   Lurie, Yoav ⁱ   Cianciara, Janusz ^j   Muir, Andrew J ^k   Cronin, Patrick W ^l   Pulkstenis, Erik ^l   Subramanian, G Mani ^l   McHutchison, John G ^k  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Alamo Medical Research   (United States)

^d Metropolitan Research   (United States)

^e Fundacin de Investigacin de Diego   (Puerto Rico)

^f SAINT LOUIS UNIVERSITY   (United States)

^g Department of Clinical Infectious Disease   (Romania)

^h Infections Limited Hawaii   (United States)

ⁱ TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^j Wojewdzki Szpital Zakany   (Poland)

^k DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^l GLAXOSMITHKLINE   (United States)

more..

Author keywords

ACHIEVE; AlbIFN; Pegylated Interferon ; Sustained Virologic Response

Indexed keywords

ALBINTERFERON ALPHA2B; PEGINTERFERON; PEGYLATED INTERFERON ALPHA 2A; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS DNA; ALBUMINOID; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN;

ADULT; ALOPECIA; ANEMIA; ANXIETY; APPETITE; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BLURRED VISION; BRONCHOSPASM; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; DYSPNEA; FATIGUE; FEMALE; FEVER; FIBROSING ALVEOLITIS; GENE FUSION; GENOTYPE; HEADACHE; HEMOPTYSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFLUENZA; INJECTION SITE ERYTHEMA; INSOMNIA; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MOOD CHANGE; MYALGIA; NAUSEA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VOMITING; WEIGHT; XEROSTOMIA; DRUG COMBINATION; HEPATITIS C, CHRONIC; MIDDLE AGED; VIROLOGY;

ADULT; ALBUMINS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 77957376504     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2010.06.066     Document Type: Article

References (24)

1. D. Lavanchy The global burden of hepatitis C Liver Int 29 Suppl 1 2009 74 81
2. C.W. Shepard, L. Finelli, and M.J. Alter Global epidemiology of hepatitis C virus infection Lancet Infect Dis 5 2005 558 567
3. S. Zeuzem Interferon-based therapy for chronic hepatitis C: current and future perspectives Nat Clin Pract Gastroenterol Hepatol 5 2008 610 622
4. M.W. Fried, M.L. Shiffman, and K.R. Reddy Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
5. S.J. Hadziyannis, H. Sette Jr, and T.R. Morgan Peginterferon alpha2a and ribavirin combination therapy in chronic hepatitis Ca randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
6. M.P. Manns, J.G. McHutchison, and S.C. Gordon Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965
7. J.G. McHutchison, E.J. Lawitz, and M.L. Schiffman Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection N Engl J Med 361 2009 580 593
8. D. Ge, J. Fellay, and A.J. Thompson Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
9. M. Sarasin-Filipowicz, E.J. Oakeley, and F.H. Duong Interferon signaling and treatment outcome in chronic hepatitis C Proc Natl Acad Sci U S A 105 2008 7034 7039
10. V.G. Bain, K.D. Kaita, and E.M. Yoshida A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients J Hepatol 44 2006 671 678
11. G.M. Subramanian, M. Fiscella, and A. Lamous-Smith Albinterferon α-2b: a genetic fusion protein for the treatment of chronic hepatitis C Nat Biotech 25 2007 1411 1419
12. S. Zeuzem, E.M. Yoshida, and Y. Benhamou Albinterferon alfa-2b dosed every two or four weeks in interferon-naive patients with genotype 1 chronic hepatitis C Hepatology 48 2008 407 417
13. P. Bedossa, and T. Poynard An algorithm for the grading of activity in chronic hepatitis C The METAVIR Cooperative Study Group Hepatology 24 1996 289 293
14. E.M. Brunt, C.G. Janney, and A.M. Di Bisceglie Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions Am J Gastroenterol 94 1999 2468 2474
15. D.R. Matthews, J.P. Hosker, and A.S. Rudenski Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 1985 412 419
16. Y. Hochberg A sharper Bonferroni procedure for multiple tests of significance Biometrika 75 1988 800 802
17. W. Wang, I. Mehrota, S. Chan, and J. Heyse Statistical considerations for noninferiority/equivalence trials in vaccine development J Biopharm Stat 16 2006 429 441
18. A.J. Muir, J.D. Bornstein, and P.G. Killenberg Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites N Engl J Med 350 2004 2265 2271
19. M. Rodriguez-Torres, L.J. Jeffers, M.Y. Sheikh Latino Study Group Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C N Engl J Med 360 2009 257 267
20. J. Midturi, M. Sierra-Hoffman, and D. Hurley Spectrum of pulmonary toxicity associated with the use of interferon therapy for hepatitis C: case report and review of the literature Clin Infect Dis 39 2004 1724 1729
21. J. Moorman, M. Saad, S. Kosseifi, and G. Krishnaswamy Hepatitis C virus and the lung: implications for therapy Chest 128 2005 2882 2892
22. G. Teuber, C. Teupe, and C. Dietrich Pulmonary dysfunction in non-cirrhotic patients with chronic viral hepatitis Eur J Int Med 13 2002 311 318
23. PEGASYS (peginterferon alfa-2a) [US package insert] August 2009 Hoffman-LaRoche Nutley, NJ
24. PegIntron (peginterferon alfa-2b) [US package insert] August 2009 Schering Corporation Kenilworth, NJ